At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Not Yet Opened 05-05 16:08:14
16.720
-0.180
-1.07%
High16.930Low16.100Vol1.35M
Open16.100D1 Closing16.900Amplitude4.91%
Mkt Cap17.74BTradable Cap17.74BTotal Shares1.06B
T/O22.32MT/O Rate0.13%Tradable Shares1.06B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations
Stock News  ·  04-30
ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations
ASCLETIS-B to Present Multiple Project Findings at ADA 2026 Scientific Sessions
Stock News  ·  04-30
ASCLETIS-B to Present Multiple Project Findings at ADA 2026 Scientific Sessions
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
prnewswire  ·  04-30
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
Ascletis reports 7.7% placebo-adjusted weight loss in ASC30 US Phase II study
Reuters  ·  04-30
Ascletis reports 7.7% placebo-adjusted weight loss in ASC30 US Phase II study
歌礼制药-B（01672）2025年业绩：营收达0.02028亿元，净亏损3.5988亿元，三大管线研发推进
Bulletin Express  ·  04-29
歌礼制药-B（01672）2025年业绩：营收达0.02028亿元，净亏损3.5988亿元，三大管线研发推进
HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%
Tiger Newspress  ·  04-28
HK Movers | Biotech Stocks Jump. Wuxi Apptec Soars 14% as 1Q Net Profit Rises 26.7%; Junshi Bio up 8%; Asymchem up Nearly 7%; Pharmaron up 4%
Sagimet Biosciences Shares Rise With Focus on Acne Treatment
Dow Jones  ·  04-27
Sagimet Biosciences Shares Rise With Focus on Acne Treatment
ASCLETIS-B Completes Patient Enrollment for US Phase II Trial of Oral GLP-1R Agonist ASC30 in Diabetes
Stock News  ·  04-27
ASCLETIS-B Completes Patient Enrollment for US Phase II Trial of Oral GLP-1R Agonist ASC30 in Diabetes
Ascletis Completes Enrollment in U.S. Phase Ii Study of Asc30, an Oral Small Molecule Glp-1R Agonist, for the Treatment of Diabetes
THOMSON REUTERS  ·  04-27
Ascletis Completes Enrollment in U.S. Phase Ii Study of Asc30, an Oral Small Molecule Glp-1R Agonist, for the Treatment of Diabetes
Ascletis completes enrollment in US Phase II diabetes trial of oral GLP-1 drug ASC30
Reuters  ·  04-27
Ascletis completes enrollment in US Phase II diabetes trial of oral GLP-1 drug ASC30
ASCLETIS-B Shares Surge Over 4% in Morning Session as Key Pipeline Drug ASC30 Nears Phase III Trial
Stock News  ·  04-24
ASCLETIS-B Shares Surge Over 4% in Morning Session as Key Pipeline Drug ASC30 Nears Phase III Trial
HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%
Tiger Newspress  ·  04-23
HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%
Assessing Ascletis Pharma (SEHK:1672) Valuation After ASC30_39 Obesity Candidate Advances Toward FDA IND Filing
Simply Wall St.  ·  04-18
Assessing Ascletis Pharma (SEHK:1672) Valuation After ASC30_39 Obesity Candidate Advances Toward FDA IND Filing
ASCLETIS-B Nears Previous Peak, But Why Are Investors Staying on the Sidelines?
Stock News  ·  04-18
ASCLETIS-B Nears Previous Peak, But Why Are Investors Staying on the Sidelines?
ASCLETIS-B Shares Surge Nearly 5% in Afternoon Trading, Approaching All-Time High as GLP-1 and Amylin Combo Enters Clinical Trials
Stock News  ·  04-17
ASCLETIS-B Shares Surge Nearly 5% in Afternoon Trading, Approaching All-Time High as GLP-1 and Amylin Combo Enters Clinical Trials
Analysts Are Optimistic We'll See A Profit From Ascletis Pharma Inc. (HKG:1672)
Simply Wall St.  ·  04-09
Analysts Are Optimistic We'll See A Profit From Ascletis Pharma Inc. (HKG:1672)
ASCLETIS-B Maintains Stable Share Base in March; No New Issuance, Public Float Fully Compliant
Bulletin Express  ·  04-08
ASCLETIS-B Maintains Stable Share Base in March; No New Issuance, Public Float Fully Compliant
ASCLETIS-B Advances Clinical Development of Fixed-Dose Combination ASC30_39 for Obesity Treatment
Stock News  ·  04-07
ASCLETIS-B Advances Clinical Development of Fixed-Dose Combination ASC30_39 for Obesity Treatment
BRIEF-Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Reuters  ·  04-07
BRIEF-Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Ascletis Accelerates Obesity Pipeline with First-in-Class Oral GLP-1/Amylin Fixed-Dose Combo; IND Targeted for Q3 2026
Bulletin Express  ·  04-07
Ascletis Accelerates Obesity Pipeline with First-in-Class Oral GLP-1/Amylin Fixed-Dose Combo; IND Targeted for Q3 2026

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--